文献简介

出版社:The International Society of Dermatology

作  者:Pablo Coto-Segura, MD,Marta Costa-Romero, MD,Pablo Gonzalvo, MD,Susana Mallo-García, MD,Jose Ramón Curto-Iglesias, MD,Jorge Santos-Juanes, MD, PhD,Pablo Coto-Segura, MD,

编  号:

关键字:parapsoriasis,bexarotene 1% gel,CTCL6

年  份:2008   点击量:981

文献摘要

In this article, we report our experience in treating parapsoriasis with bexarotene 1% gel. Parapsoriasis refers to a papulosquamous eruption on the skin characterized by its distribution (trunk and proximal extremities), asymptomatic nature, and chronic course. Based on the clinicopathologic similarities of parapsoriasis and early mycosis fungoides/ cutaneous T-cell lymphoma (MF/CTCL), the exact nosology of parapsoriasis has been challenged, with a hypothesis that all variants of parapsoriasis (large plaque, small plaque, and digitate) are synonymous with early MF. Nevertheless, the original TNM staging scheme of CTCL6 recognized parapsoriasis as a distinct precursor stage (T0N0M0) and defined T0 CTCL as the presence of lesions clinically and/or histologically suggestive of CTCL. Because bexarotene (a rexinoid) 1% gel shows a response rate of up to 63% in Stage Ia–IIa MF/CTCL, we sought to evaluate the tolerability, safety, and efficacy of bexarotene 1% gel in patients with parapsoriasis.

    在这篇文章中,我们报道了采用1%蓓萨罗丁凝胶治疗副银屑病的经验。副银屑病是以分布在皮肤上(躯干和近端肢体)的丘疹鳞屑性爆发为特点,无自觉症状,慢性病程。假设所有副银屑病的变种(大斑块型、小斑块型和点状型)是早期MF的同义词,基于副银屑病和早期蕈样真菌病/皮肤T细胞淋巴瘤(MF/CTCL)临床病理的相似之处,副银屑病的确切病理分类学受到了挑战。尽管如此,CTCL的最初TNM分期方案承认副银屑病是一种独特的前驱阶段(T0N0M0)并定义T0 CTCL为临床病变/或组织学上暗示有CTCL。由于蓓萨罗丁(一种维甲酸)1%凝胶在la-lla MF/ CTCL阶段的反应率高达63%,因此我们试图在副银屑病患者中评估了1%蓓萨罗丁凝胶的耐受性、安全性和有效性。